[1] Hom RK, Katzenellenbogen JA. Technetiam-99m-labeled receptor-specific small-molecule radiopharmaceuticals:recent developments and encouraging results[J]. Nucl Med Biol, 1997, 24:485~498.
[2] Eckelman WC, Gibson RE. The path from in vitro autoradiography to in vivo autoradingraphy by external imaging[A].Stumf WE(ed):Autoradiography and Correlatie Imaging[M]. New York:Academic Press, 1995. 529~556.
[3] Shi W, Johnston CF, Buchanan KD, et al.Localization of neuroendocrine tumors with 111In DTPA-octreotide scintigraphy(Octreoscan):a comparative study with CT and MR imaging[J]. Q J Med, 1998, 91:295~301.
[4] Rijks LJM, Bakker PJM, van Tienhoven G, et al.Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVB[J]. J Clin Oncol, 1997, 25:2536~2545.
[5] Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons[J]. J Nucl Med, 1996, 1009~1015.
[6] Johns CS, Bowen WD, Fisher SJ, et al. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl) ethyl]-3-[125I]-iodo-4-methoxybenzamide (P[125I]) MBA) forimaging breast cancer[J]. Nucl Med Biol, 1999, 26:377~382.
[7] John CS, Lim BB, Vilner BJ, et al. Substituted halogenated arylsulfonamides:a new class of sigma receptor binding tumor imaging agents[J]. J Med Chem, 1998, 41:2445~2450.
[8] Waterhouse RN, Chapman J, Izard B, et al.Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents:initial studies in mouse tumor models[J].Nucl Med Biol, 1997, 24:587~593.
[9] Johns CS, Lim BB, Geyer BC, et al.99mTc-labeled σ-receptor-binding complex:synthesis,characterization, and specific binding to human ductal breast carcinoma (T47D) cells[J]. Bioconjugate Chem, 1997, 8:304~309.
[10] Eisenhut M, Mohammed A, Miser W, et al. Melano-ma affine Tc-99 m complexes of N-(2-dithylamino-ethyl) benzamides[J]. J Nucl Med, 1999, 40:120P.
[11] Stanley JG, Goldsmith SJ. Receptor imaging:competitive or complementary to antibody imaging?[J]. Semin Nucl Med, 1997, 27:85~93.